Compare TDY & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDY | ZTS |
|---|---|---|
| Founded | 1960 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4B | 32.5B |
| IPO Year | 2000 | 2012 |
| Metric | TDY | ZTS |
|---|---|---|
| Price | $679.67 | $73.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $693.71 | $154.18 |
| AVG Volume (30 Days) | 412.1K | ★ 5.8M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | 9.70 | ★ 10.05 |
| EPS | ★ 10.20 | 3.08 |
| Revenue | $1,020,400,000.00 | ★ $9,467,000,000.00 |
| Revenue This Year | $5.54 | $5.63 |
| Revenue Next Year | $5.08 | $4.77 |
| P/E Ratio | $66.04 | ★ $24.62 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $483.02 | $71.45 |
| 52 Week High | $697.67 | $160.48 |
| Indicator | TDY | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 45.19 |
| Support Level | $627.29 | $73.42 |
| Resistance Level | $690.19 | $78.74 |
| Average True Range (ATR) | 14.65 | 3.08 |
| MACD | 0.46 | -0.06 |
| Stochastic Oscillator | 72.35 | 28.33 |
Teledyne Technologies Inc provides enabling technologies to sense, analyze and distribute information for industrial growth markets that require advanced technology and high reliability. The firm operates in four segments: Digital Imaging, Instrumentation, Aerospace and Defense Electronics, and Engineered Systems. The Digital Imaging segment, that derives maximum revenue, includes high-performance sensors, cameras and systems, within the visible, infrared and X-ray spectra for use in industrial, government and medical applications, as well as MEMS and high-performance, high-reliability semiconductors including analog-to-digital and digital-to-analog converters. Geographically, the company operates in United States, Europe, Asia, and All other.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.